WO2002047650A1 - Utilisation d'au moins une sapogenine pour prevenir les signes du viellissement cutane - Google Patents
Utilisation d'au moins une sapogenine pour prevenir les signes du viellissement cutane Download PDFInfo
- Publication number
- WO2002047650A1 WO2002047650A1 PCT/FR2001/003727 FR0103727W WO0247650A1 WO 2002047650 A1 WO2002047650 A1 WO 2002047650A1 FR 0103727 W FR0103727 W FR 0103727W WO 0247650 A1 WO0247650 A1 WO 0247650A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sapogenin
- dioscorea
- natural extract
- use according
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- the invention relates to the cosmetic use of at least one sapogenin or of a natural extract containing it to prevent the signs of skin aging, in particular the loss of elasticity and / or tone of the skin, by inhibition of collagenase activity.
- It also relates to the cosmetic use of at least one sapogenin or of a natural extract containing it to prevent the loss of firmness of the human skin of the face and / or of the neck.
- Human skin is made up of two compartments, namely a surface compartment, the epidermis, and a deep compartment, the dermis.
- the natural human epidermis is mainly composed of three types of cells which are the keratinocytes, very majority, the melanocytes and the Langerhans cells. Each of these cell types contributes by its own functions to the essential role played in the body by the skin.
- the dermis provides the epidermis with solid support. It is also its nourishing element.
- H consists mainly of fibroblasts and an extracellular matrix itself composed mainly of collagen, elastin and a substance, called the fundamental substance, components synthesized by the fibroblast.
- leukocytes There are also leukocytes, mast cells or tissue macrophages. It is also crossed by blood vessels and nerve fibers.
- Collagen fibers which ensure the solidity of the dermis.
- Collagen fibers are made up of fibrils sealed to each other, thus forming more than ten different types of structures.
- the solidity of the dermis is largely due to the good quality entanglement of collagen fibers packed against each other in all directions. Collagen fibers participate in the firmness, elasticity and tone of the skin and / or mucous membranes.
- the collagen fibers are constantly renewed, but this renewal decreases with age, which leads to thinning of the dermis.
- various factors cause collagen to degrade, with all the consequences that can be expected on the structure and / or firmness of the skin and / or mucous membranes.
- collagen fibers are sensitive to certain enzymes called collagenases. Degradation of collagen fibers results in the appearance of soft, wrinkled skin that humans, preferring the appearance of smooth and taut skin, have always sought to combat.
- Collagenases are part of a family of enzymes called metalloproteinases (MMPs) - which are themselves members of a family of proteolytic enzymes (endoproteases) which have a zinc atom coordinated to 3 cysteine residues and a methionine in their active site and which degrade the macromolecular components of the extracellular matrix and the basal laminae at neutral pH (collagen, elastin, etc.).
- MMPs metalloproteinases
- endoproteases endolytic enzymes
- Prolonged exposure to ultraviolet radiation has the effect of stimulating the expression of collagenases, particularly MMP-1. This is one of the components of photo-induced skin aging.
- One of the aims of the present invention is therefore to be able to have a product which has a collagenase inhibiting effect and if possible no significant side effects.
- Sapogenins are compounds resulting from the acid hydrolysis of saponosides, which are themselves heterosides of very high molecular weight present in the plant kingdom. These compounds have. common is a steroid structure comprising a variable number of hydroxyl and or oxo substituents and / or a variable number of double bonds. They are known as natural chemical precursors of steroid hormones and described, as such, as constituents of choice for various cosmetic or pharmaceutical preparations.
- Diosgenin has already been described as an anti-inflammatory (Yamada et al., Am. J. Physiol., 273: G355-G364, 1997) and as a slimming active by its action on adipocytes (WO 00/30603).
- the extracts of Dioscorea opposita and Dioscorea tokora, which contain diosgenin, have also been described as effective for hydrating the skin and thus softening it (JP-10 194947 and JP-2000 143488).
- the subject of the invention is the cosmetic use of at least one sapogenin or a natural extract containing it to prevent the signs of skin aging, in particular the loss of elasticity and / or of tone of the skin and / or the formation of fine lines and wrinkles, by inhibiting the activity of collagenases.
- It also relates to the cosmetic use of at least one sapogenin or of a natural extract containing it to prevent the loss of firmness of the human skin of the face and / or the neck.
- the sapogenin used according to the invention can be chosen from: diosgenin, hecogenin, smilagenin, sarsapogenin, tigogenin, yamogenin and yuccagenin.
- Diosgenin can be extracted from tubers of wild yam by a process successively comprising: hydrolysis of the heterosides in mineral acid medium (possibly after fermentation and drying of the tubers); and filtration of the insoluble fraction, which is then neutralized, washed and treated with an apolar solvent. Other extraction methods can however be used. Diosgenin is also commercially available from SIGMA under the name Diosgenin sales representative.
- natural extracts means any plant extract containing one or more sapogenins, after any treatment intended to hydrolyze the saponosides, such as an extract of wild yam rhizome, which contains diosgenin, or an extract of leaf agave containing hecogenin and tigogenin, or an extract of Liliaceae, in particular of the genus Smilax or Yucca, containing smilagenin and sarsapogenin, such as an extract of sarsaparilla root.
- an extract of wild yam rhizome which contains diosgenin
- an extract of leaf agave containing hecogenin and tigogenin or an extract of Liliaceae, in particular of the genus Smilax or Yucca, containing smilagenin and sarsapogenin, such as an extract of sarsaparilla root.
- the natural extract used according to the invention can be obtained from plant material from a whole plant or part of a plant.
- This extract can be prepared from any plant material cultivated in vivo or in vitro.
- the term “in vivo culture” means any culture of the conventional type, that is to say in soil in the open air or in a greenhouse, or even above ground.
- the term “in vitro culture” means all of the techniques known to those skilled in the art which artificially make it possible to obtain a plant or part of a plant. The selection pressure imposed by the physico-chemical conditions during the growth of plant cells in vitro makes it possible to obtain standardized plant material which is available throughout the year unlike plants cultivated in vivo.
- a natural extract is used, obtained from at least one plant of the genus Dioscorea, preferably obtained from the rhizome of wild yam.
- Dioscorea belongs to the family Dioscoraceae and is made up of hundreds of species of which only a few contain sapogenins. Among these, mention may be made, for example, of Dioscorea villosa, Dioscorea opposita, Dioscorea composita, Dioscorea mexicana, Dioscorea tokora and Dioscorea floribunda.
- the extract of the invention is preferably prepared from plant material from the Dioscorea villosa and / or Dioscorea opposita species.
- Such an extract is available in particular from the company ACTIVE ORGANICS under the trade name Actigen Y ® .
- the amount of extract usable according to the invention is of course a function of the desired effect and can therefore vary to a large extent.
- composition according to the invention is generally suitable for topical use and therefore it contains a physiologically acceptable medium, that is to say compatible with the skin, its integuments and / or the mucous membranes.
- This composition can be in all the galehic forms normally used in the cosmetic and dermatological fields, and it can in particular be in the form of an aqueous solution possibly gelled, of a dispersion of the lotion type possibly biphasic, of an emulsion obtained by dispersion of a fatty phase in an aqueous phase (O / W) or vice versa (W / O), or of a triple emulsion (W / O / W or O / W / O) or of a vesicular type dispersion ionic and / or non-ionic.
- These compositions are prepared according to the usual methods.
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. . It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, in particular in the form of a stick. It can be used as a care product and / or as a make-up product for the skin.
- the composition of the invention can also contain the adjuvants usual in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, fillers, filters, pigments, odor absorbers and coloring matters.
- the amounts of these various adjuvants are those conventionally used in the field under consideration, and for example from 0.01 to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase or into the lipid vesicles.
- these adjuvants will be chosen so as not to harm the desired properties of the sapogenins or natural extracts according to the invention.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% by weight relative to the total weight of the composition.
- the oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
- the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition.
- oils which can be used in the invention mention may be made of mineral oils (petroleum jelly oil), oils of vegetable origin (avocado oil, soybean oil), oils of animal origin (lanolin), oils of synthesis (perhydrosqualene), silicone oils (cyclomethicone) and fluorinated oils (perfluoropolyethers). It is also possible to use fatty alcohols (cetyl alcohol), fatty acids, waxes (carnauba wax, ozokerite).
- emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid esters of polyethylene glycol such as PEG-20 stearate, and fatty acid and glycerin esters such as glyceryl stearate .
- hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
- carboxyvinyl polymers carboxyvinyl polymers
- acrylic copolymers such as acrylate / alkyl acrylate copolymers
- polyacrylamides polysaccharides
- natural gums and clays and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
- the composition also contains at least one other metalloproteinase inhibitor, such as lycopene, isoflavones, their derivatives or plant extracts containing them, in particular soy extracts (sold for example by the company ICHIMARU PHARCOS under the trade name Flavosterone SB), red clover, flax, kakkon or sage.
- at least one other metalloproteinase inhibitor such as lycopene, isoflavones, their derivatives or plant extracts containing them, in particular soy extracts (sold for example by the company ICHIMARU PHARCOS under the trade name Flavosterone SB), red clover, flax, kakkon or sage.
- the composition according to the invention may contain an agent stimulating the growth and / or metabolism of fibroblasts, such as plant proteins or polypeptides, extracted in particular from soybeans (for example a soybean extract marketed by the company LSN under the name Eleseryl SH-VEG 8 or marketed by the company SILAB under the trade name Raffermine), and / or an agent promoting the differentiation and / or growth and / or metabolism of keratinocytes, such as retinol or its derivatives or certain plant extracts such as a lupine extract marketed by the company SILAB under the trade name Structurine, and / or an agent stimulating the skin microcirculation such as a bitter orange extract sold by the company Silab under the trade name Remoduline.
- an agent stimulating the growth and / or metabolism of fibroblasts such as plant proteins or polypeptides, extracted in particular from soybeans (for example a soybean extract marketed by the company LSN under the name Eleseryl SH-VEG 8 or marketed by the company SILAB under the trade
- concentration of these optional additional agents in the composition according to the invention can vary from 0.0001 to 20% by weight and is preferably between 0.001 and 5% by weight, relative to the total weight of the composition.
- composition according to the invention may also contain an agent promoting collagen synthesis, such as ascorbic acid or its derivatives, an exfoliating agent such as ⁇ - or ⁇ -hydroxy acids, a protective agent or UV filter, an improving agent the skin barrier such as ceramides, and / or a moisturizing agent such as polyois or calcium pantothenate.
- an agent promoting collagen synthesis such as ascorbic acid or its derivatives, an exfoliating agent such as ⁇ - or ⁇ -hydroxy acids, a protective agent or UV filter, an improving agent the skin barrier such as ceramides, and / or a moisturizing agent such as polyois or calcium pantothenate.
- UV filters which are particularly suitable for use in the present invention are:
- the concentration of these UV filters in the composition according to the invention can range from 0.01 to 30% by weight, and preferably from 0.1 to 10% by weight, relative to the total weight of the composition. These filters can be used alone or in combination to obtain the desired Sun Protection Factor in the UVA and / or UVB.
- the effect of a wild yam extract on the inhibition of collagenase activity produced by Clostridium Histolyticum was evaluated. Although different from a human enzyme, this collagenase is used because of its ability to digest human collagen.
- the positive reference is phenanthroline tested at concentrations of 1 mM, 0.5 mM and 0.25 mM in ethanol.
- the used wild yam rhizome extract is an extract of the species Dioscorea villosa marketed by the company Active Organics under the trade name Actigen Y ®, which was tested at concentrations of 2%, 1%, 0.5% and 0.1% (in a test buffer consisting of collagenase at 0.125 Units / ml, Tris at 0.1 M and Ca Cl 2 at 5mM) of a stock solution at 2 mg / ml in a water / 20/80 ethanol, which corresponds to final concentrations of 40, 20, 10 and 2 ⁇ g / ml.
- the control consists of collagenase without product to be tested.
- the activity of the control constitutes 100% of collagenase activity and therefore 0% of inhibition of said activity
- the products were pre-incubated with the enzyme for 10 minutes at room temperature, then the DQ-gelatin was added and the fluorescence obtained at the degradation of the substrate was recorded for 10 minutes (excitation 485nm; emission 538nm) on a SpectraMax spectrofluorimeter (Molecular Devices); the results were processed using Soft Max Pro software.
- Example 2 Emulsion in the form of a cream
- This cream is useful, in daily applications on the face and the neck, to prevent the signs of cutaneous aging and in particular the loss of firmness of the skin.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01270315A EP1351661A1 (fr) | 2000-12-11 | 2001-11-26 | Utilisation d'au moins une sapogenine pour prevenir les signes du viellissement cutane |
JP2002549225A JP2004515523A (ja) | 2000-12-11 | 2001-11-26 | 皮膚の老化の兆候を予防するための、少なくとも一のサポゲニン、またはこれを含有する天然抽出物の使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR00/16074 | 2000-12-11 | ||
FR0016074A FR2817747B1 (fr) | 2000-12-11 | 2000-12-11 | Utilisation d'au moins une sapogenine, ou d'un extrait naturel en contenant, pour prevenir les signes du vieillissement cutane |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002047650A1 true WO2002047650A1 (fr) | 2002-06-20 |
Family
ID=8857485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2001/003727 WO2002047650A1 (fr) | 2000-12-11 | 2001-11-26 | Utilisation d'au moins une sapogenine pour prevenir les signes du viellissement cutane |
Country Status (5)
Country | Link |
---|---|
US (1) | US20030152597A1 (fr) |
EP (1) | EP1351661A1 (fr) |
JP (1) | JP2004515523A (fr) |
FR (1) | FR2817747B1 (fr) |
WO (1) | WO2002047650A1 (fr) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1250121B1 (fr) * | 2000-01-12 | 2006-04-19 | L'oreal | Utilisation de la dhea ou certaines de ses derives pour ameliorer l'aspect papyrace de la peau |
EP2011481A2 (fr) | 2007-07-06 | 2009-01-07 | L'Oreal | Composition de protection solaire contenant l'association d'un polymère semi-cristallin et de particules de latex creuses |
EP2014277A1 (fr) | 2007-07-12 | 2009-01-14 | L'Oreal | Composition photoprotectrice fluide aqueuse à base d'un polymère polyamide à terminaison amide tertiaire |
EP2016932A2 (fr) | 2007-07-09 | 2009-01-21 | L'Oréal | Utilisation pour la coloration de la peau de l'acide dehydroascorbique ou de ses derives polymeres ; procedes de soin et/ou de maquillage |
EP2119429A1 (fr) | 2008-05-14 | 2009-11-18 | L'Oréal | Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone ; procede de photostabilisation du derive de dibenzoylmethane |
EP2174644A1 (fr) | 2008-10-08 | 2010-04-14 | L'oreal | Composition cosmétique contenant un dérivé de dibenzoylméthane et un composé dithiolane; procédé de photostabilisation du dérivé de dibenzoylmethane |
EP2191869A1 (fr) | 2008-12-01 | 2010-06-02 | L'oreal | Procédé de coloration artificielle de la peau utilisant un mélange de caroténoide et de colorant vert lipophile ; nouveau mélange de colorants lipophiles ; composition |
WO2011073279A2 (fr) | 2009-12-18 | 2011-06-23 | L'oreal | Procédé de traitement cosmétique impliquant un composé apte à condenser in situ |
WO2011151203A2 (fr) | 2010-06-03 | 2011-12-08 | L'oreal | Processus de traitement cosmétique utilisant un revêtement à base d'un copolymère contenant des blocs de polyamide et des blocs de polyéther |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040009130A1 (en) * | 2002-07-08 | 2004-01-15 | Detore Donna Marie | Compositions for treating keratinous surfaces |
FR2855753B1 (fr) * | 2003-06-03 | 2007-09-14 | Dermo Cosmologie Lab De | Composition a base de diosgenine applicable par voie topique |
FR2892635B1 (fr) * | 2005-10-28 | 2012-11-09 | Engelhard Lyon | Substance pour restaurer une co-expression et une interaction normales entre les proteines lox et nrage |
FR2916977A1 (fr) * | 2007-06-06 | 2008-12-12 | Engelhard Lyon Sa | STIMULATION DE LA SYNTHESE DES RECPTEURS MCR1, MCR2 ET µ OPIOIDE. |
WO2009088109A1 (fr) * | 2008-01-04 | 2009-07-16 | Biospectrum, Inc. | Composition contenant de la diosgénine pour le blanchiment de la peau |
JP2009256243A (ja) * | 2008-04-17 | 2009-11-05 | Noevir Co Ltd | 保湿剤、抗老化剤、抗酸化剤、皮膚外用剤及び機能性経口組成物 |
JP5383384B2 (ja) * | 2009-08-27 | 2014-01-08 | 株式会社ノエビア | 抗老化剤、抗酸化剤、美白剤、及び免疫賦活剤 |
JP5718700B2 (ja) * | 2011-03-29 | 2015-05-13 | 花王株式会社 | 新規セスタテルペン化合物、抗菌剤及び皮膚外用剤 |
KR101395004B1 (ko) | 2011-10-13 | 2014-05-15 | 원광대학교산학협력단 | 단마 추출물을 유효 성분으로 함유하는 피부 노화의 예방과 개선을 위한 조성물 |
KR101987420B1 (ko) * | 2017-01-09 | 2019-06-12 | 주식회사 아미코스메틱 | 야생얌뿌리, 참깨, 눈연꽃 및 금은화 추출물을 포함하는 피부 보습 및 피부 진정용 화장료 조성물 |
JP2021187789A (ja) * | 2020-06-01 | 2021-12-13 | 株式会社リアルメイト | ヒートショックプロテイン誘導剤、一酸化窒素産生促進剤、抗更年期障害剤、抗加齢剤、化粧品および食品または飲料 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992009262A1 (fr) * | 1990-11-21 | 1992-06-11 | Lvmh Recherche | Utilisation de saponines de medicago pour la preparation de compositions cosmetiques ou pharmaceutiques, notamment dermatologiques favorisant le renouvellement de l'epiderme, stimulant la repousse des cheveux, ou retardant leur chute |
US5166176A (en) * | 1986-12-29 | 1992-11-24 | Obagi Zein E | Composition for healing damaged skin |
JPH07196526A (ja) * | 1994-01-11 | 1995-08-01 | Takano Co Ltd | コラゲナーゼ阻害剤 |
JPH08283172A (ja) * | 1995-04-14 | 1996-10-29 | Kose Corp | 活性酸素消去剤及びこれを含有する皮膚外用剤 |
WO1997027835A1 (fr) * | 1996-02-02 | 1997-08-07 | Unilever Plc | Composition d'hygiene corporelle |
JPH09328410A (ja) * | 1996-06-06 | 1997-12-22 | Yushiro Chem Ind Co Ltd | 化粧料及びその製造方法 |
WO1998006418A1 (fr) * | 1996-08-09 | 1998-02-19 | Mannatech, Inc. | Compositions a base d'hydrates de carbone de plantes comme supplements dietetiques |
JP2000169320A (ja) * | 1998-12-03 | 2000-06-20 | Nippon Zetokku Kk | 細胞賦活剤、それを含む皮膚外用剤及び皮膚洗浄剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US225677A (en) * | 1880-03-16 | winters | ||
US223893A (en) * | 1880-01-27 | Charles deavs | ||
MX164619B (es) * | 1988-03-02 | 1992-09-09 | Vicente Parrilla Cerrillo | Composicion para el tratamiento de lesiones cutaneas |
US5723149A (en) * | 1990-11-21 | 1998-03-03 | Lvmh Recherche | Use of medicago saponins for the preparation of cosmetic or pharmaceutical compositions, especially dermatological compositions, promoting renewal of the epidermis, stimulating hair regrowth or delaying hair loss |
FR2799759B1 (fr) * | 1999-10-14 | 2001-11-30 | Oreal | Composition, notamment cosmetique, comprenant une sapogenine |
-
2000
- 2000-12-11 FR FR0016074A patent/FR2817747B1/fr not_active Expired - Fee Related
-
2001
- 2001-11-26 JP JP2002549225A patent/JP2004515523A/ja active Pending
- 2001-11-26 WO PCT/FR2001/003727 patent/WO2002047650A1/fr not_active Application Discontinuation
- 2001-11-26 US US10/182,730 patent/US20030152597A1/en not_active Abandoned
- 2001-11-26 EP EP01270315A patent/EP1351661A1/fr not_active Withdrawn
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166176A (en) * | 1986-12-29 | 1992-11-24 | Obagi Zein E | Composition for healing damaged skin |
WO1992009262A1 (fr) * | 1990-11-21 | 1992-06-11 | Lvmh Recherche | Utilisation de saponines de medicago pour la preparation de compositions cosmetiques ou pharmaceutiques, notamment dermatologiques favorisant le renouvellement de l'epiderme, stimulant la repousse des cheveux, ou retardant leur chute |
JPH07196526A (ja) * | 1994-01-11 | 1995-08-01 | Takano Co Ltd | コラゲナーゼ阻害剤 |
JPH08283172A (ja) * | 1995-04-14 | 1996-10-29 | Kose Corp | 活性酸素消去剤及びこれを含有する皮膚外用剤 |
WO1997027835A1 (fr) * | 1996-02-02 | 1997-08-07 | Unilever Plc | Composition d'hygiene corporelle |
JPH09328410A (ja) * | 1996-06-06 | 1997-12-22 | Yushiro Chem Ind Co Ltd | 化粧料及びその製造方法 |
WO1998006418A1 (fr) * | 1996-08-09 | 1998-02-19 | Mannatech, Inc. | Compositions a base d'hydrates de carbone de plantes comme supplements dietetiques |
JP2000169320A (ja) * | 1998-12-03 | 2000-06-20 | Nippon Zetokku Kk | 細胞賦活剤、それを含む皮膚外用剤及び皮膚洗浄剤 |
Non-Patent Citations (4)
Title |
---|
DATABASE WPI Week 199702, Derwent World Patents Index; AN 1997-017313, XP002176866 * |
DATABASE WPI Week 199810, Derwent World Patents Index; AN 1998-105073, XP002176865 * |
DATABASE WPI Week 200048, Derwent World Patents Index; AN 2000-527354, XP002176867 * |
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 11 (C - ) * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1250121B1 (fr) * | 2000-01-12 | 2006-04-19 | L'oreal | Utilisation de la dhea ou certaines de ses derives pour ameliorer l'aspect papyrace de la peau |
EP2011481A2 (fr) | 2007-07-06 | 2009-01-07 | L'Oreal | Composition de protection solaire contenant l'association d'un polymère semi-cristallin et de particules de latex creuses |
EP2016932A2 (fr) | 2007-07-09 | 2009-01-21 | L'Oréal | Utilisation pour la coloration de la peau de l'acide dehydroascorbique ou de ses derives polymeres ; procedes de soin et/ou de maquillage |
EP2014277A1 (fr) | 2007-07-12 | 2009-01-14 | L'Oreal | Composition photoprotectrice fluide aqueuse à base d'un polymère polyamide à terminaison amide tertiaire |
EP2119429A1 (fr) | 2008-05-14 | 2009-11-18 | L'Oréal | Composition cosmetique contenant un derive de dibenzoylmethane et un derive de pyrrolidinone ; procede de photostabilisation du derive de dibenzoylmethane |
EP2174644A1 (fr) | 2008-10-08 | 2010-04-14 | L'oreal | Composition cosmétique contenant un dérivé de dibenzoylméthane et un composé dithiolane; procédé de photostabilisation du dérivé de dibenzoylmethane |
EP2191869A1 (fr) | 2008-12-01 | 2010-06-02 | L'oreal | Procédé de coloration artificielle de la peau utilisant un mélange de caroténoide et de colorant vert lipophile ; nouveau mélange de colorants lipophiles ; composition |
WO2011073279A2 (fr) | 2009-12-18 | 2011-06-23 | L'oreal | Procédé de traitement cosmétique impliquant un composé apte à condenser in situ |
WO2011073280A2 (fr) | 2009-12-18 | 2011-06-23 | L'oreal | Procédé de traitement cosmétique impliquant un composé apte à condenser in situ résistant |
WO2011151203A2 (fr) | 2010-06-03 | 2011-12-08 | L'oreal | Processus de traitement cosmétique utilisant un revêtement à base d'un copolymère contenant des blocs de polyamide et des blocs de polyéther |
Also Published As
Publication number | Publication date |
---|---|
FR2817747B1 (fr) | 2004-12-03 |
US20030152597A1 (en) | 2003-08-14 |
JP2004515523A (ja) | 2004-05-27 |
EP1351661A1 (fr) | 2003-10-15 |
FR2817747A1 (fr) | 2002-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002047650A1 (fr) | Utilisation d'au moins une sapogenine pour prevenir les signes du viellissement cutane | |
EP1090628B1 (fr) | Utilisation du lycopène dans des compositions destinées à traiter les signes cutanés du vieillissement | |
FR2814950A1 (fr) | Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement | |
EP1656970A1 (fr) | Composition cosmétique comprenant un hydrolysat de protéines de riz et un agent augmentant la synthèse des glycosaminoglycanes | |
FR2877220A1 (fr) | Utilisation de composes d'uree pour lutter contre les signes du vieillissement cutane | |
FR2811561A1 (fr) | Composition, notamment cosmetique, renfermant la dhea et/ou un precurseur ou derive chimique ou biologique de celle-ci, et un inhibiteur de metalloproteinase | |
FR2812544A1 (fr) | Utilisation d'au moins un extrait d'au moins un vegetal du genre salvia dans des compositions destinees a traiter les signes cutanes du vieillissement | |
EP1275372B1 (fr) | Composition cosmétique ou dermatologique comprenant un dérivé de N-Acylaminoamide et un inhibiteur de métalloprotéinase | |
FR2788435A1 (fr) | Utilisation d'un extrait d'un vegetal du genre rosmarinus dans des compositions destinees a traiter les signes cutanes du vieillissement | |
EP1172094B1 (fr) | Composition, notamment cosmétique, comprenant la DHEA et/ou un précurseur ou dérivé, et au moins un composé augmentant la synthèse des glycosaminoglycanes | |
EP1352643B1 (fr) | Utilisation d'une sapogénine ou d'un extrait naturel en contenant, pour lisser les rides et ridules d'expression | |
FR2755367A1 (fr) | Utilisation d'un extrait de potentille erecta dans le domaine de la cosmetique et de la pharmacie, notamment de la dermatologie | |
EP2139445A2 (fr) | Utilisation de l'acide gamma-aminobutyrique en tant qu'agent depigmentant | |
EP0948313B1 (fr) | Utilisation d'un extrait de resine d'okoume, dans les domaines cosmetique et pharmaceutique, notamment dermatologiques | |
EP1375509A1 (fr) | Utilisation d'une sapogénine, ou d'un extrait naturel en contenant, pour le traitement des peaux sèches oligoséborrhéiques | |
FR2926021A1 (fr) | Utilisation de derives c-glycoside a titre d'actif vasculaire | |
EP0985409A1 (fr) | Utilisation en cosmétique d'acides gras | |
FR2821549A1 (fr) | Utilisation d'un carotenoide pour traiter les signes du vieillissement | |
EP1331923A2 (fr) | Utilisation de l'association d'un extrait de rosmarinus et d'un carotenoide | |
WO2002005776A1 (fr) | Composition, notamment cosmetique, renfermant la dhea ou certaines de ses derives, et un carotenoïde | |
FR3114027A1 (fr) | Principe actif cosmétique comprenant un extrait de son et de germe d’Oryza sativa. | |
FR3130602A1 (fr) | Composition contenant l'association d'un C-glycoside et de l'escine pour le soin du contour des yeux | |
FR3082748A1 (fr) | Extrait de parties aeriennes de germandree lisse, composition comprenant ledit extrait pour la reparation cutanee | |
FR2828400A1 (fr) | Composition cosmetique ou dermatologique comprenant une association entre de l'igf1 et/ou un compose mimetique de l'igf1, et au moins un retinoide et/ou au moins un derive de retinoide | |
FR3090382A1 (fr) | Miel d’euphorbe comme actif favorisant la régénération tissulaire |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001270315 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 549225 Kind code of ref document: A Format of ref document f/p: F |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10182730 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001270315 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001270315 Country of ref document: EP |